Atea Pharmaceuticals (AVIR) Research & Development: 2019-2024
Historic Research & Development for Atea Pharmaceuticals (AVIR) over the last 6 years, with Dec 2024 value amounting to $144.1 million.
- Atea Pharmaceuticals' Research & Development fell 52.36% to $27.5 million in Q4 2022 from the same period last year, while for Dec 2022 it was $81.9 million, marking a year-over-year decrease of 51.00%. This contributed to the annual value of $144.1 million for FY2024, which is 26.14% up from last year.
- Per Atea Pharmaceuticals' latest filing, its Research & Development stood at $144.1 million for FY2024, which was up 26.14% from $114.2 million recorded in FY2023.
- Atea Pharmaceuticals' Research & Development's 5-year high stood at $167.2 million during FY2021, with a 5-year trough of $38.0 million in FY2020.
- For the 3-year period, Atea Pharmaceuticals' Research & Development averaged around $113.4 million, with its median value being $114.2 million (2023).
- Its Research & Development has fluctuated over the past 5 years, first soared by 339.75% in 2021, then crashed by 51.00% in 2022.
- Over the past 5 years, Atea Pharmaceuticals' Research & Development (Yearly) stood at $38.0 million in 2020, then spiked by 339.75% to $167.2 million in 2021, then plummeted by 51.00% to $81.9 million in 2022, then soared by 39.43% to $114.2 million in 2023, then climbed by 26.14% to $144.1 million in 2024.